Jefferies Group LLC Reiterates $124.00 Price Target for TESARO, Inc. (TSRO)
TESARO, Inc. (NASDAQ:TSRO) has been assigned a $124.00 price objective by equities researchers at Jefferies Group LLC in a report issued on Thursday. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential upside of 13.71% from the stock’s current price.
Several other analysts also recently weighed in on the stock. Credit Suisse Group set a $190.00 price objective on shares of TESARO and gave the stock a “buy” rating in a research report on Friday. Evercore ISI started coverage on shares of TESARO in a research report on Wednesday. They issued an “in-line” rating and a $121.00 price target for the company. Robert W. Baird reiterated a “neutral” rating and issued a $140.00 price target (down previously from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target on shares of TESARO in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $173.47.
TESARO (NASDAQ TSRO) traded up 1.65% during midday trading on Thursday, reaching $110.85. 394,208 shares of the company were exchanged. The firm has a 50-day moving average price of $126.76 and a 200-day moving average price of $148.14. The company’s market capitalization is $6.01 billion. TESARO has a 52 week low of $83.26 and a 52 week high of $192.94.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by $0.30. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.28) EPS. Equities research analysts anticipate that TESARO will post ($8.68) earnings per share for the current fiscal year.
In other news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at $748,155.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 40.50% of the stock is currently owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Vident Investment Advisory LLC bought a new stake in TESARO during the first quarter worth $351,000. Botty Investors LLC bought a new stake in TESARO during the second quarter worth $140,000. Meeder Asset Management Inc. bought a new stake in TESARO during the first quarter worth $177,000. Nordea Investment Management AB bought a new stake in TESARO during the second quarter worth $167,000. Finally, Oppenheimer Asset Management Inc. increased its stake in TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.